The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical Outcomes of TAVI or SAVR in Men and Women with Aortic Stenosis at Intermediate Operative Risk: a post hoc analysis of the randomized SURTAVI trial

DOI: 10.4244/EIJ-D-20-00303

1. Department of Interventional Cardiology, Erasmus University Medical Centre, Rotterdam, The Netherlands, Netherlands
2. Department of Cardiothoracic Surgery and Interventional Cardiology, Houston-Methodist-Debakey Heart and Vascular Center, Houston, TX
3. Department of Cardiology, Riverside Methodist – Ohio Health, Columbus, OH
4. Departments of Cardiothoracic Surgery and Interventional Cardiology, Spectrum Health Hospitals, Grand Rapids, Michigan
5. Department of Interventional Cardiology, University Hospital Bern, Bern, Switzerland
6. Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
7. Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA
8. Interventional Cardiology, Saint Thomas Heart, Ascension Medical Group, Nashville, TN
9. Interventional Cardiology, Cardiovascular Institute of the South, Houma, LA
10. Interventional Cardiology, Baylor Scott & White Heart and Vascular Hospital, Dallas, TX
11. Cardiothoracic Surgery, Baylor Scott & White Heart and Vascular Hospital, Dallas, TX
12. International Centre for Circulatory Health, NHLI, Imperial College London, London, United Kingdom
13. Department of Interventional Cardiology, Beth Israel Deaconess Medical Center, Boston, MA
Disclaimer:

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.

Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.

To read the full content of this article, please log in to download the PDF.

AIMS: In patients with aortic stenosis randomized to transcatheter aortic valve implantation
(TAVI) or surgical aortic valve replacement (SAVR), sex-specific differences in complication rates are unclear in intermediate-risk patients. METHODS AND RESULTS: 1,660 intermediate-risk patients underwent TAVI with a supra-annular, self-expanding bioprosthesis or SAVR. The population was stratified by sex and treatment modality (female TAVI=366, male TAVI=498, female SAVR=358, male SAVR=438). The primary endpoint was a composite of all-cause mortality or disabling stroke at two years. Compared to males, females had a smaller body surface area, a higher Society of Thoracic Surgeons score (4.7±1.6% vs. 4.3±1.6%, p<0.01) and more frailty. Men required more concomitant revascularization (23% vs. 16%). All-cause mortality or disabling stroke at two years was similar between TAVI and SAVR for females (10.2% vs. 10.5%, p=0.90) and males
(14.5% vs. 14.4%, p=0.99); the difference between females and males was 10.2% vs. 14.5%, for TAVI (p=0.08) and 10.5% vs. 14.4%, SAVR (p=0.13). Functional status improvement was more pronounced after TAVI for females than males. CONCLUSIONS: Aortic valve replacement, either by surgical or transcatheter approach, appears similarly effective and safe for males and females at intermediate surgical risk. Functional status appears to improve most in females after TAVI.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Rotational and orbital atherectomy, in-stent restenosis, clinical outcomes of stent thrombosis, coronary physiology in TAVI patients, invasive strategies for advanced heart failure, and more